Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 23 h ago

Grace Therapeutics, Inc.: ADAR1 Capital Management, LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 17 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

ADAR1 Capital Management, LLC filed an amended Schedule 13G with the SEC disclosing a change to its beneficial ownership stake in Grace Therapeutics, Inc. The amendment, filed under SEC accession number 0001104659-26-128739, updates the investment firm's previously reported position in the clinical-stage biopharmaceutical company. Schedule 13G filings are required of investors holding passive stakes above 5% of a company's shares, making the amendment a signal of possible shifts in institutional ownership. The filing did not specify the size or direction of the stake change in the headline disclosure. Investors will watch for further 13G or 13D filings to clarify whether ADAR1 is accumulating or trimming its position in Grace Therapeutics.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

ADAR1 Capital Management, LLC, Grace Therapeutics, Inc.